Context: Momordica charantia (Cucurbitaceae) is extensively distributed in tropical areas, and it is traditionally used as antidiabetic. Nevertheless, few studies supporting the metabolic effects of its foliage extracts have been reported elsewhere. Aims: To evaluate the effects of M. charantia foliage extract (MCh) on blood glucose and lipids levels in animal models of hyperglycemia. The anti-inflammatory and antioxidant properties together with the acute toxicity and genotoxic effects were also assessed. Methods: An MCh powder was obtained by spray-drying techniques. The anti-hyperglycemic and hypolipidemic effects of MCh were evaluated in the glucose tolerance test and the alloxan-induced diabetes, respectively. The in vitro and ex vivo MCh antioxidant effects were assessed against the 2,2´-azinobis3-ethylbenzothiazoline-6-sulfonic acid (ABTS), peroxyl, and superoxide anion radicals. The MCh anti-inflammatory effects were also assessed together with its toxicological profile by means of the Acute Toxic Class Method, and the chromosome aberration assay. Results: MCh administered orally diminished the glucose and lipids levels in normoglycemic healthy rats and alloxan-induced hyperglycemic mice. Strong in vitro free radical scavenging effects was demonstrated by MCh against ABTS, peroxyl, and superoxide anion radicals. The extract also improved the free radical scavenging ability of diabetic mice serum. Moreover, MCh reduced the weight of cotton-induced granulomas in mice, the exudate volume, and its leukocyte counts in carrageenan-induced pleurisy in rats. Very low MCh toxicity was also verified. Conclusions: The hypoglycemic, hypolipidemic, anti-inflammatory, and antioxidant activities here observed make the spray-drayed powder from M. charantia foliage extract an interesting alternative for the correction of diabetes and its complications.
1 March 2021 in Journal of Pharmacy & Pharmacognosy Research
Context: JM-20 is a hybrid synthetic molecule, which is based on a multimodal drug design paradigm for cerebrovascular disease. In addition to its neuroprotective effects, JM-20 also decreased sciatic nerve chronic constriction injury (CCI)-induced mechanical hypersensitivity in rats. JM-20 has a strong mitoprotective ability, and its effects could be in correspondence with the mitotoxicity hypothesis for paclitaxel-induced painful peripheral neuropathy. Aims: To evaluate the efficacy of the JM-20 to reduce neuropathic pain manifestations induced by the administration of paclitaxel in rats. Methods: In this study was implemented a rat model of painful peripheral neuropathy, produced by the chemotherapeutic agent paclitaxel, to determine whether JM-20 (10 mg/kg, p.o) could prevent the development of neuropathic pain during the exposure to paclitaxel. As well as to determine whether JM-20 (20 mg/kg, p.o) could reverse the established neuropathic pain. Mechanical behavioral assessment using von Frey filaments applied to the hind paws was applied before, during, and after treatments for 35 days. Results: Giving JM-20 during the exposure to paclitaxel significantly reduced the severity of mechanical allodynia and mechanical hyperalgesia. Moreover, JM-20 significantly reduced both established neuropathic pain manifestations. There was no evidence of tolerance to the effect during three days of dosing, and a long-term effect was observed after JM-20 discontinuation. Conclusions: JM-20 may be clinically relevant for both the prevention and treatment of paclitaxel-induced painful peripheral neuropathy.
1 January 2019 in Journal of Pharmacy & Pharmacognosy Research
Context: Chitosan has received attention as a functional, sustainably renewable, nontoxic and biodegradable biopolymer for pharmaceutical applications such as healing agent. Aims: To design a semisolid pharmaceutical form (ointment), employing 1% chitosan as an active pharmaceutical ingredient. Methods: The formulation was carried out through D-optimal mixing design, with a linear model. Variation components evaluated were the concentration of sodium hydroxide, water and anhydrous lanolin. Variables included those of response pH and extensibility. Three batches were produced, and the physical and chemical stability of the ointment was assessed through stress and shelf-life tests for 24 months. Physical-chemical parameters studied included organoleptic characteristics, chitosan content, rheological behavior, apparent viscosity, pH and extensibility. Wound healing activity was also tested for burns damage model in rats. Results: The mixture design showed that the best formulation was the one containing 0.12% sodium hydroxide, 20.0% anhydrous lanolin and 40.0% water, with the mechanical-structural behavior characteristics of a semisolid product. This product had healing effects and showed adequate physical chemical stability during the time under study. Conclusions: The results of this study suggest that 1% chitosan ointment design favors scarring in the second-degree burn damage model in rats skin applied for 14 days at the rate of daily administration.